Pembrolizumab trials for Non-small Cell Lung Cancer (NSCLC)

All Pembrolizumab trials · All Non-small Cell Lung Cancer (NSCLC) trials

Phase breakdown

Recruiting trials studying Pembrolizumab for Non-small Cell Lung Cancer (NSCLC)

• A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
  NCT05920356 · Phase: Phase 3 · Ages: 18 Years to 100 Years · Sex: All (male and female) · 418 locations
• A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
  NCT07227168 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
  NCT07361510 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 279 locations
• A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
  NCT07223047 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 8 locations
• Pembrolizumab for Advanced NSCLC and PS 2-3
  NCT05589818 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
  NCT06170788 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 220 locations
• Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC
  NCT07777822 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
  NCT06162221 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 93 locations

Common questions

How many trials study Pembrolizumab for Non-small Cell Lung Cancer (NSCLC)?

8 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.